Locations:
Search IconSearch
December 30, 2020/Cancer

Cleveland Clinic Surgeon Completes First Clinical Use of Newly Approved Ablation Device for Large Liver Tumors

The technology could reduce complications by offering patients an alternative to open liver surgeries

2015058_11-20-20_025_MK-Hero_650x450

Cleveland Clinic is the first hospital in the world to use a recently FDA-approved ablation technology that can destroy large liver tumors. The new device from Medtronic is called the Emprint™ HP Ablation System with Thermosphere™ Technology. The minimally invasive procedure uses a single needle connected to a powerful 150-watt microwave generator that can burn a malignant liver tumor as large as 2.4 inches (6 cm).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Eren Berber, MD, Director of Cleveland Clinic’s Surgical Liver Tumor Ablation Program, led a team that successfully used the device in October to treat a patient who had a 2.4-inch liver tumor. Following the minimally invasive procedure, the patient is doing well and postoperative imaging shows no trace of the tumor. Since the first case in October at Cleveland Clinic, Dr. Berber’s team has treated four more patients with large liver tumors using the technology.

“We’ve been using the previous versions of this technology,” says Dr. Berber. “But the challenge was that with a single needle, we were only able to create 4-centimeter burns. This technology is able to utilize 150 watts of power compared to the 100 watts that we used before. We’re also now able to create 6- or 7-centimeter burns with a single stick. This allowed us to treat larger tumors more confidently.”

Cleveland Clinic has been using ablation technologies to treat smaller tumors up to about 1.5 inches (4 cm) in diameter and not amenable to liver resection. Dr. Berber and his team have treated close to 1,000 patients with ablation and more than 200 patients with microwave ablation. It was because of this extensive experience with the technique and device that Dr. Berber was selected as the first clinical user. “This microwave ablation technology is very powerful, and if you don’t use it well, you can cause damage to the liver, you can cause bleeding or you can disrupt the tumor,” says Dr. Berber. “As the technology becomes more advanced and more powerful, gaining ablation expertise through experience becomes even more important.”

Advertisement

Understanding the procedure

To perform the procedure, a laparoscopic camera and an ultrasound probe are inserted in the abdomen through two small incisions. Then, a microwave needle is inserted through the skin into the liver tumor. When ready, the generator delivers heat to burn and destroy the lesion.

“Over the last six years, ablation technology evolved to incorporate microwave technology, which gives us a more homogeneous heating of the tissues by achieving higher temperatures,” explains Dr. Berber. “There is more balanced heating, and we can now reach higher tissue temperatures. Because of that, the success of ablation has greatly improved; the failure rate went down from 20% to 40% to about 10% or less.”

Identifying candidates

Dr. Berber notes that the best candidates for this procedure for treatment of large liver tumors are those with comorbidities which rendered them poor candidates for a major operation that would involve liver resection (cutting). This includes patients with multiple systemic diseases, heart problems, lung problems, or elderly patients who have decreased functional status who cannot tolerate a major operation. This procedure would be a good alternative for patients who would require surgery to remove a large portion of their liver. Open liver surgical procedures are associated with longer operative times and hospital stays, as well as higher incidence of complications.

“The goal is to offer the best treatment option for patients depending on their unique health condition,” says Dr. Berber In the hands of an experienced surgical team, the laparoscopic ablation technique benefits the patient, who experiences better postoperative recovery, less pain, a quicker return to normal life, and a lower risk of an incisional hernia compared with traditional open surgery.”

Advertisement

Dr. Berber has a consulting agreement with Medtronic and has received honoraria for consulting activities. He notes that his consulting agreements do not affect his choice of the best treatment option for his patients.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad